Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | New therapies in AML with Steven Knapper

Steven Knapper • 2 Apr 2019
BSH 2019
Leukemia CPX-351 Cytarabine Daunorubicin Gemtuzumab ozogamicin Midostaurin
RATIFY

Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He gives us an overview of new therapies in acute myeloid leukemia (AML), which has seen an explosion of new agents and approvals.

More from Steven Knapper

Challenges and perspectives on the management of AML within the UK's NHS framework
1:35
Challenges and perspectives on the management of AML within the UK's NHS framework
Steven Knapper • 8 Dec 2024
NCRI AML18: CPX-351 vs standard daunorubicin & cytarabine plus fractionated GO in older pts with AML
3:50
NCRI AML18: CPX-351 vs standard daunorubicin & cytarabine plus fractionated GO in older pts with AML
Steven Knapper • 8 Dec 2024
Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trial
1:55
Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trial
Steven Knapper • 8 Dec 2024
Developments in the treatment of patients with FLT3-mutated AML
3:26
Developments in the treatment of patients with FLT3-mutated AML
Steven Knapper • 1 May 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals